Compare BWXT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWXT | PODD |
|---|---|---|
| Founded | 1867 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 21.0B |
| IPO Year | 2010 | 2007 |
| Metric | BWXT | PODD |
|---|---|---|
| Price | $206.44 | $241.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | $202.93 | ★ $352.86 |
| AVG Volume (30 Days) | 826.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.57 | ★ 3.48 |
| Revenue | $1,687,738,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $18.99 | $22.19 |
| Revenue Next Year | $16.44 | $18.68 |
| P/E Ratio | $81.19 | ★ $71.53 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $84.21 | $230.08 |
| 52 Week High | $220.57 | $354.88 |
| Indicator | BWXT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 35.41 |
| Support Level | $193.28 | $240.78 |
| Resistance Level | $209.22 | $275.10 |
| Average True Range (ATR) | 8.87 | 9.66 |
| MACD | 0.10 | 0.90 |
| Stochastic Oscillator | 83.53 | 4.17 |
BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.